These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 1956036)
1. Synthesis and biological evaluation of hydroxamate-based iron chelators. Bergeron RJ; Wiegand J; McManis JS; Perumal PT J Med Chem; 1991 Nov; 34(11):3182-7. PubMed ID: 1956036 [TBL] [Abstract][Full Text] [Related]
2. Hydroxamate-based iron chelators: combinatorial syntheses of desferrioxamine B analogues and evaluation of binding affinities. Poreddy AR; Schall OF; Osiek TA; Wheatley JR; Beusen DD; Marshall GR; Slomczynska U J Comb Chem; 2004; 6(2):239-54. PubMed ID: 15002973 [TBL] [Abstract][Full Text] [Related]
3. Triphenylphosphonium-desferrioxamine as a candidate mitochondrial iron chelator. Alta RYP; Vitorino HA; Goswami D; Terêsa Machini M; Espósito BP Biometals; 2017 Oct; 30(5):709-718. PubMed ID: 28770399 [TBL] [Abstract][Full Text] [Related]
4. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Glickstein H; Breuer W; Loyevsky M; Konijn AM; Shanzer A; Cabantchik ZI Blood; 1996 Jun; 87(11):4871-8. PubMed ID: 8639861 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates. Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097 [TBL] [Abstract][Full Text] [Related]
6. Novel trihydroxamate-containing peptides: design, synthesis, and metal coordination. Ye Y; Liu M; Kao JL; Marshall GR Biopolymers; 2006; 84(5):472-89. PubMed ID: 16705688 [TBL] [Abstract][Full Text] [Related]
7. Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis. Lytton SD; Mester B; Libman J; Shanzer A; Cabantchik ZI Blood; 1994 Aug; 84(3):910-5. PubMed ID: 8043872 [TBL] [Abstract][Full Text] [Related]
8. Chelation of thallium by combining deferasirox and desferrioxamine in rats. Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432 [TBL] [Abstract][Full Text] [Related]
10. Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. Tsafack A; Golenser J; Libman J; Shanzer A; Cabantchik ZI Mol Pharmacol; 1995 Feb; 47(2):403-9. PubMed ID: 7870051 [TBL] [Abstract][Full Text] [Related]
11. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460 [TBL] [Abstract][Full Text] [Related]
12. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Chaston TB; Lovejoy DB; Watts RN; Richardson DR Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494 [TBL] [Abstract][Full Text] [Related]
13. Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores. Golenser J; Tsafack A; Amichai Y; Libman J; Shanzer A; Cabantchik ZI Antimicrob Agents Chemother; 1995 Jan; 39(1):61-5. PubMed ID: 7695330 [TBL] [Abstract][Full Text] [Related]
14. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro. Jeremy JY; Kontoghiorghes GJ; Hoffbrand AV; Dandona P Biochem J; 1988 Aug; 254(1):239-44. PubMed ID: 3140797 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold. Rodriguez-Lucena D; Gaboriau F; Rivault F; Schalk IJ; Lescoat G; Mislin GL Bioorg Med Chem; 2010 Jan; 18(2):689-95. PubMed ID: 20036563 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. Dobbin PS; Hider RC; Hall AD; Taylor PD; Sarpong P; Porter JB; Xiao G; van der Helm D J Med Chem; 1993 Aug; 36(17):2448-58. PubMed ID: 8355246 [TBL] [Abstract][Full Text] [Related]
17. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Richardson D; Ponka P; Baker E Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330 [TBL] [Abstract][Full Text] [Related]
18. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Lim CK; Kalinowski DS; Richardson DR Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550 [TBL] [Abstract][Full Text] [Related]
19. Deferoxamine, the newly developed iron chelator LK-614 and N-alpha-acetyl-histidine in myocardial protection. Koch A; Loganathan S; Radovits T; Sack FU; Karck M; Szabó GB Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):181-4. PubMed ID: 19914924 [TBL] [Abstract][Full Text] [Related]
20. Structural alterations in desferrioxamine compatible with iron clearance in animals. Bergeron RJ; Liu ZR; McManis JS; Wiegand J J Med Chem; 1992 Dec; 35(25):4739-44. PubMed ID: 1469701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]